Vicor Technologies, Inc. CEO David Fater Discusses Company’s Product Commercialization Status With Shareholder Vision in Exclusive Video Interview

BOCA RATON, FL--(Marketwire - April 08, 2010) - Vicor Technologies, Inc. (OTCBB: VCRT) today announced that David Fater, Chairman, President, and CEO, is presently featured in a video interview at Shareholder Vision. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

In the interview, Mr. Fater discusses Vicor's first commercial sales of its PD2i Analyzer™ to U.S. physicians, how physicians are using the PD2i Analyzer™ and receiving reimbursement for its use under existing CPT codes, and the Company's revenue model for the PD2i Analyzer™. Additionally, he shares the status of clinical trials being conducted in collaboration with the U.S. Army Institute for Surgical Research on its PD2i VS™ (Vital Sign), which risk stratifies severity of injury to improve battlefield and civilian trauma triage, and clinical trials being conducted in collaboration with the University of Rochester and the Catalan Institute of Cardiovascular Sciences in Barcelona on its PD2i CA™ (Cardiac Analyzer), which identifies patients at risk of sudden cardiac death.

"During the past three months, we've made significant strides toward implementing our strategic plan. We are pleased to have this opportunity to share our accomplishments with Shareholder Vision," stated Mr. Fater.

To listen to the interview, please click here: http://www.shareholdervision.com/2010/04/vicor-fater/

About Shareholder Vision
Shareholder Vision produces exclusive high-quality, broadband resolution video interviews with senior management of small, publicly-traded companies.

About Vicor Technologies, Inc.
Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of sudden cardiac death.

Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases.

The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to obtain FDA approval of the PD2i VS™ (Vital Sign) for military and civilian applications, and for the PD2i CA™ (Cardiac Analyzer); our ability to continue to receive financing sufficient to continue operations and complete the critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-05

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati: biotechnology medical devices diagnostics sudden cardiac death hear rate variability